Wednesday, February 1, 2023

FDA pulls Covid antibody treatment because it’s not effective against dominant omicron variants

Trending News

  • The FDA, in a notice Wednesday, said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.
  • U.S. health officials have warned that people with weak immune systems face a heightened risk from Covid this winter, because omicron subvariants threaten to knock out antibody treatments.
  • President Joe Biden has called on people with weak immune systems to consult with their physicians about what extra precautions they should take this winter to stay safe.

Read Full News

Disclaimer: This story is generated from RSS Feed and has not been created or edited by Waba News. Publisher: CNBC


Please enter your comment!
Please enter your name here

- Advertisement -
Latest News

Muni Long: 5 Things To Know About Singer/Songwriter Nominated For 3 Grammy Awards

Muni Long has written songs for some of today's biggest stars like Rihanna and Mariah Carey. Find out all...
- Advertisement -
- Advertisement -

More Stories Like This